We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Advanced Melanoma

Expert Opinion / Cases · February 01, 2021

50-year-old Male With Extensive Disease Progression After 3 Lines of Treatment

Written by
Viola Franke MD

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Ari VanderWalde

    It appears that the patient started on adjuvant nivolumab. Did the patient complete a full year of treatment, or did he progress while on adjuvant therapy? If the former, it is reasonable to restart nivolumab therapy, preferably together with ipilimumab. Even if the latter, there is some Phase II evidence that adding ipilimumab to PD-1 therapy after progression on PD1 may result in a response rate of up to 25%. The definitive trial, S1616, has yet to report out, but in the absence of this, it remains a reasonable option before embarking on more heroic therapies.


  • Sep 21, 2021

    Pending Moderator approval.
    Delete

Further Reading